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Abstract
Purpose of Review Megalin is well known for its role in the reabsorption of proteins from the ultrafiltrate. Recent studies suggest
that megalin also reabsorbs renin and angiotensinogen. Indeed, without megalin urinary renin and angiotensinogen levels
massively increase, and even prorenin becomes detectable in urine.
Recent Findings Intriguingly, megalin might also contribute to renal angiotensin production, as evidenced from studies in
megalin knockout mice. This review discusses these topics critically, concluding that urinary renin-angiotensin system compo-
nents reflect diminished reabsorption rather than release from renal tissue sites and that alterations in renal renin levels or
megalin-dependent signaling need to be ruled out before concluding that angiotensin production at renal tissue sites is truly
megalin dependent.
Summary Future studies should evaluate megalin-mediated renin/angiotensinogen transcytosis (allowing interstitial angiotensin
generation), and determine whether megalin prefers prorenin over renin, thus explaining why urine normally contains no
prorenin.
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Introduction
It is generally believed that renin-angiotensin system (RAS)
activity in the kidney is independent of RAS activity in the
circulation. Indeed, angiotensin (Ang) II levels in the kidney
are several orders of magnitude higher than the levels of Ang
II in blood and cannot be explained by uptake from the circu-
lation [1, 2]. Virtually all renal Ang II is cell associated, either
bound to Ang II type 1 (AT1) receptors on the cell surface or
present intracellularly [3]. Studies in AT receptor knockout
animals revealed that the intracellular presence of Ang II is
dependent on AT1 receptor-mediated internalization, i.e., there
is no evidence for intracellular Ang II generation [4]. Renal
angiotensin generation therefore most likely occurs in the in-
terstitial space. Remarkably, despite evidence for local
angiotensinogen synthesis in the kidney, such generation, like
circulating angiotensin generation, depends on liver-derived
angiotensinogen [5, 6, 7•, 8]. With an identical substrate
source, opposing changes in RAS activity in blood and kidney
must be due to other RAS regulatory mechanisms, like the
(local) release of renin and its precursor prorenin, the uptake
of angiotensinogen from blood (possibly involving more than
simple diffusion), and/or local alterations in ACE activity. For
instance, in diabetes, the circulating RAS is suppressed, while
renal RAS activity is increased [9]. This has been attributed to
prorenin synthesis by the principal cells of the collecting duct,
evidenced by increased renin activity in the collecting duct
and elevated urinary renin levels in this condition [10–12].
However, a recent study in diabetic mice challenged this view
and concluded that the increase in collecting duct renin under
diabetic conditions reflects renin binding and not local synthe-
sis [13••]. Moreover, the elevated urinary renin levels were
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due to enhanced glomerular filtration of plasma renin in com-
bination with incomplete reabsorption by megalin, i.e., they
did not reflect renin release from renal tissue sites (like the
collecting duct). Surprisingly, megalin knockout even affected
renal angiotensin generation [14••, 15•]. This review describes
the role of megalin as a novel determinant of renal and urinary
RAS activity.
What Is Megalin?
Megalin is a single transmembrane protein consisting of 4655
amino acids with a molecular weight of 600 kDa. It has a large
extracellular domain, a transmembrane region, and a small
intracellular tail of 209 amino acids. It was originally known
as glycoprotein 330 [16]. Megalin belongs to the low-density
lipoprotein receptor (LDLR) superfamily [17] and contains
four regions that consist of cysteine-rich complement-type re-
peats, four regions that consist of growth factor repeats spaced
by eight YWTD repeats, and a single epidermal growth factor
(EGF)-like repeat in its extracellular juxtamembrane region.
The regions containing complement-type repeats are believed
to be important for ligand binding, while the regions contain-
ing growth factor repeats are likely required for pH-dependent
ligand dissociation in the endosomal compartment [18, 19].
The overall structure of megalin resembles LDLR-related pro-
tein 1 (LRP1), and therefore, megalin is also known as LRP2
[17]. The very large extracellular domain allows megalin to
bind multiple ligands [20], and until now, > 50 ligands for
megalin have been described, including albumin, insulin,
insulin-like growth factor, lipoproteins, and drugs like
aprotinin and polymyxin B [18, 21, 22].
Although megalin was initially identified as an antigen in
glomerular podocytes, the expression of megalin in the glo-
merulus is negligible versus that in the proximal tubule [16,
18, 23–26]. Outside the kidney, megalin is also observed in
absorptive epithelia in the lung, eye, gall bladder, placenta,
and the (para)thyroid gland [18].
Megalin forms a 1:1 complex with the extracellular protein
cubilin on the apical plasma membrane of proximal tubule
cells, and together, they mediate the endocytosis of ultrafiltrate
proteins for subsequent lysosomal degradation and retrieval of
their ligands and constituent amino acids into the blood. This
prevents massive protein loss via urine. Megalin is a fast-
recycling receptor with a long half-life, thereby making it ideal
for reabsorption. Its endocytosis depends on the enzymatic
activity of an inositol 5-phosphatase encoded by the gene
oculocerebrorenal syndrome protein 1 (OCRL1) [27]
(Fig. 1). The cytosolic tail of megalin is important for recycling
and degradation [28]. Among others, it binds the small GTPase
Rab11, and dominant negative mutations in Rab11 result in
diminished apical delivery of megalin due to disturbed
recycling [29]. Autosomal recessive hypercholesterolemia
(ARH), an adaptor protein that binds megalin in a similar man-
ner as the LDLR and clathrin, retains megalin in the recycling
endosomes, so that it cannot reappear on the cell surface [30].
Furthermore, phosphorylation of the cytosolic tail by glycogen
synthase kinase 3β also inhibits its recycling from endosomes
back to the plasma membrane [31]. Fast recycling requires
rapid disruption of the megalin-ligand complex through acid-
ification in endosomes, a process depending on voltage-gated
chloride channel 5 (ClC-5) and vacuolar H+-ATPase. Their
colocalization is believed to allow ClC-5 to move in chloride
as a counter-ion to the proton that is pumped by the vacuolar
H+-ATPase [32, 33], thus ensuring optimal acidification.
Genetic Mutations Affecting Megalin
LRP2 mutations, as occurring in the Donnai-Barrow/Facio-
Oculo-Acoustico-Renal syndrome, result in impaired megalin
function. Patients display proteinuria [34], hypercalciuria,
nephrocalcinosis, nephrolithiasis, and focal segmental
glomerulosclerosis [35]. Genome-wide association studies
confirmed the link between LRP2 and proteinuria [36].
Interestingly, patients with mutations in the genes encoding
for OCRL1 (Lowe syndrome) and ClC-5 (Dent’s disease) also
display megalin dysfunction and proteinuria [37–39]. This can
be explained based on the importance of OCRL1 and ClC-5
for megalin endocytosis and endosomal acidification, respec-
tively (Fig. 1).
Megalin and Kidney Disease
Megalin knockout mice display increased albumin excretion
[40] and are protected against kidney damage resulting from a
high-fat diet [24]. Similar protective effects are derived from
megalin inhibition (e.g., with cilastatin) in relationship to
acute kidney injury due to the uptake of nephrotoxic drugs
like vancomycin and cisplatin [41]. Anti-brush border anti-
body disease or anti-LRP2 nephropathy involves the deposit
of large amounts of circulating IgG through megalin in the
renal tubule. This might explain why autoantibodies induce
acute kidney injury [42]. Excess albumin, as occurring in pa-
tients with chronic kidney disease (CKD), directly contributes
to the development and progression of CKD by inducing
tubulointerstitial inflammation and fibrosis in a megalin-
dependent manner [43]. Urinary excretion of megalin associ-
ates with renal oxidative stress in CKD [44, 45], while
megalin excretion in both urine and urinary extracellular ves-
icles correlates with the progression of albuminuria in type 2
diabetes mellitus [46, 47]. The latter implies that urinary
megalin could be a biomarker for diabetic nephropathy. Yet,
renal megalin expression is decreased in diabetes [13••], al-
though increases have been observed in the early stage of type
2 diabetes [48, 49]. Among the factors that lower megalin is
Ang II [50].
   30 Page 2 of 7 Curr Hypertens Rep           (2020) 22:30 
Megalin and Urinary RAS Components
Both renin and angiotensinogen can be detected in urine, al-
beit at very low levels (a few percent or less) when expressed
as a percentage of their concomitant plasma concentrations
[12, 51]. Prorenin is undetectable in urine [12]. The latter is
not due to prorenin-renin conversion in urine [12].
Remarkably, renin and angiotensinogen massively rise (up
to 40-fold) in urine of patients with Dent’s disease or Lowe
syndrome [52], and the same occurs in urine of megalin
knockdown mice [15•], or after megalin inhibition with lysine
[53]. In fact, prorenin can also be detected in the urine of
patients with Dent’s disease or Lowe syndrome. From these
data, it can be concluded that RAS components are present in
the ultrafiltrate, but normally are largely (> 95%) reabsorbed
in a megalin-dependent manner [15•, 52–54], and possibly
near-completely in the case of prorenin. Indeed, all 3 RAS
components are filtered through the glomerulus and co-
localize with megalin in the kidney [49, 54]. In fact, since both
renin and prorenin are smaller than albumin, relatively larger
amounts of renin and prorenin will pass the glomerulus in
comparison with albumin. Not surprisingly, the glomerular
sieving coefficients of renin, prorenin, and angiotensinogen
increase after damaging the glomerular filtration barrier [52],
e.g., in diabetes. Moreover, in mice, the rise in urinary renin
after lysine was smaller under diabetic conditions than under
normal conditions (≈ 10-fold versus ≈ 100-fold) [13••]. This is
suggestive for disturbed tubular reabsorption. Therefore, the
elevated urinary RAS component levels in diabetes do not
reflect release from renal (tubular) tissue sites but are the con-
sequence of enhanced filtration from blood plasma in combi-
nation with reduced reabsorption [13••]. One more condition
where urinary renin, prorenin, and angiotensinogen levels are
unexpectedly high is preeclampsia [55]. Like in diabetes, this
may reflect enhanced filtration; to what degree megalin is
downregulated in this condition is still unknown. It is also
unknown whether megalin-dependent reabsorption is differ-
ent for renin and prorenin.
Megalin and Renal Angiotensin Production
After establishing that renal angiotensin generation depends on
liver-derived angiotensinogen, while renal angiotensinogen
staining was limited to proximal tubule cells expressing
megalin, Matsusaka and colleagues studied whether megalin
is a determinant of angiotensin production at renal tissue sites
[14••]. It was observed that proximal tubule-specific knockout
of megalin in mice did not affect renal Ang II levels, although
such knockout did massively increase urinary angiotensinogen
levels. Yet, when inducing podocyte injury with the
immunotoxin LMB2, the well-known rise in renal
angiotensinogen and Ang II levels no longer occurred without
tubular megalin. As a consequence, the Ang II-mediated Na+
reabsorption via sodium-hydrogen exchanger 3 and the epithe-
lial sodium channel were diminished, and thus the megalin
knockout mice excreted 5 times more sodium after podocyte
Fig. 1 Megalin and its associated
molecules in the proximal tubule.
EGF, epidermal growth factor;
OCRL1, oculocerebrorenal
syndrome protein 1; ClC-5,
voltage-gated chloride channel 5;
ARH, autosomal recessive
hypercholesterolemia; (P)RR,
(pro)renin receptor; V-ATPase,
vacuolar H+-ATPase; CUB,
complement subcomponents C1r
and C1s, fibropellin, and bone
morphogenetic protein 1
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injury. In contrast with these findings, Ye et al. observed a
profound (> 70%) drop in renal Ang II levels in wild type mice
after megalin suppression based on the application of megalin
antisense oligonucleotides (ASO) [15•]. The ASO approach did
not affect circulating Ang II and resulted in the expected huge
increase in urinary renin and angiotensinogen. Yet, even more
surprising, megalin ASO reduced the atherosclerotic lesions in
LDLR KO mice fed a high-fat diet. This suggests that renal
Ang II, generated in a megalin-dependent manner, contributes
to atherosclerosis. However, an alternative explanation might
be that the ASO approach additionally interfered with megalin
at extrarenal sites (as opposed to the proximal tubule-specific
knockout applied by Matsusaka et al. [14••]), and that this un-
derlies the beneficial effect on atherosclerosis. Indeed, megalin
has been reported to contribute to Ang II internalization and
signaling [50, 56] and binds lipoproteins. Ideally therefore,
these data are confirmed in the proximal tubule-specific knock-
out model. With regard to renal angiotensin generation, both
studies imply that this is reduced without megalin, either selec-
tively under pathological conditions (following podocyte inju-
ry) or possibly already under healthy conditions. Here it is
important to note that we do not know the renal renin levels
in these studies, and thus a final possibility is that megalin
knockout has altered these levels (although it did not affect
renin gene expression). In fact, under most circumstances, it is
variation in renin and not variation in angiotensinogen, which
underlies variations in renal angiotensin generation, and even
an angiotensinogen suppression of > 95% can be matched by a
rise in renin [7•]. Indeed, renin rises of > 100-fold are easily
achievable [57], and renal Ang II levels are unaltered when
angiotensinogen is suppressed by 98% [7•].
When proposing a role for megalin in renal angiotensin
generation, the question is how exactly this might occur.
Obviously, endocytosis should then not result in
angiotensinogen destruction. According to Wilson et al.
[58], internalized angiotensinogen traffics intact to the mito-
chondria in isolated proximal tubules. However, given the
absence of intracellular angiotensin generation [4], the impli-
cations of this finding are unclear. An attractive hypothesis
would be that angiotensinogen is transcytosed to the
basolateral membrane and released into the renal interstitium
(Fig. 2). Such megalin-dependent transcytosis has been ob-
served for albumin in rats [59, 60] and even for
angiotensinogen in opossum kidney cells [54]. Diffusion of
hepatic angiotensinogen from the circulation into the intersti-
tial space has been reported decades ago as the most impor-
tant, if not only, source of tissue angiotensin production [61].
It seems unlikely that the minute amounts of angiotensinogen
in the ultrafiltrate under healthy conditions would contribute
significantly to the renal interstitial angiotensinogen levels.
However, under conditions of excessive protein/
angiotensinogen leakage, assuming that megalin-mediated
transcytosis takes place, it may indeed increase interstitial
angiotensinogen and contribute to renal angiotensin produc-
tion. In the case of prorenin, the acidic pH in the endosomes
might even lead to prorenin activation, since a low pH results
in non-proteolytic removal of the prosegment from the enzy-
matic cleft [62]. Yet, in previous studies, we were unable to
Fig. 2 Megalin-mediated
endocytosis of prorenin, renin,
and angiotensinogen, resulting in
lysosomal degradation and/or
transcytosis and subsequent
release into the renal interstitium,
allowing angiotensin generation.
The low pH in endosomes may
result in non-proteolytic prorenin
activation (i.e., removal of the
prosegment from the enzymatic
cleft, resulting in “open,” active
prorenin)
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show release of activated prorenin from prorenin-synthesizing
cells, possibly because activated prorenin rapidly returns to
the non-activated state in a neutral pH environment [63].
Megalin and the (Pro)Renin Receptor
Numerous studies have investigated the so-called (pro)renin
receptor as a novel component of the RAS over the last 2
decades. Although this receptor was initially reported to bind
and activate prorenin [64], later studies revealed that the
prorenin levels required to allow such interaction are many
orders above its in vivo levels, even under pathological con-
ditions [65, 66]. Hence, this concept is now being abandoned,
also because it has become clear that the (pro)renin receptor is
an accessory protein of vacuolar H+-ATPase (also known as
ATP6AP2), and thus has important functions beyond the
RAS, like facilitating vesicle trafficking, intracellular signal-
ing, and lipid metabolism [67–70]. As such, it may also con-
tribute to megalin sorting and recycling, since it determines
endosomal acidification in concert with ClC-5 (Fig. 1). In
agreement with this concept, ATP6AP2 inhibition impaired
megalin protein regulation in Drosophila epithelial cells
[71]. Thus, via megalin, the (pro)renin receptor may display
a relationship with renin and prorenin.
Conclusions and Remaining Questions
Megalin is a multi-ligand receptor mainly (but not exclusively!)
expressed in the kidney, determining protein reabsorption in the
proximal tubule. Both genetic mutations and kidney disease
(e.g., diabetes, preeclampsia) affect its function and expression,
thus contributing to kidney pathology. Since megalin also binds
RAS components, an intriguing new concept is that it might
even play a role in angiotensin generation at renal tissue sites. If
so, its internalization should not result in destruction, but, for
instance, via transcytosis, result in angiotensinogen release into
the renal interstitial space. Such release would obviously de-
pend on the level of angiotensinogen in the ultrafiltrate
(reflecting podocyte injury) and tubular megalin expression,
thus explaining why renal angiotensin generation may not al-
ways occur in concert with angiotensin generation in the circu-
lation. Furthermore, megalin determines the level of RAS com-
ponents in urine, and in the absence of megalin (like in Dent’s
disease or Lowe syndrome), urinary renin and angiotensinogen
levels can easily rise by 2 orders of magnitude [52]. As such,
urinary renin and angiotensinogen components do not reflect
release from renal tissue sites (like the collecting duct) but rather
diminished uptake of filtered RAS components. Given the vir-
tual absence of prorenin (despite its filtration) in urine, except
under conditions where megalin function is disturbed, it seems
that megalin prefers prorenin over renin. Future studies should
now address this concept, e.g., making use of megalin-
expressing cells like proximal tubule epithelial cells and
BrownNorway Rat yolk sac epithelial cells. Such studies might
also shed light on RAS component transcytosis. Additionally,
in vivo renal angiotensin generation should be verified in the
presence or absence of megalin and during inhibition of hepatic
angiotensinogen synthesis, ruling out that alterations in renal
renin levels and/or megalin-dependent signaling underlie the
observed changes in kidney Ang II levels after megalin knock-
out [14••, 15•]. Knowledge on megalin expression in pre-
eclampsia might shed light on the occurrence of prorenin in
urine of women with preeclampsia [55]. Finally, we need to
know what determines renin uptake in the collecting duct, re-
ported recently by Tang et al. [13••], given that megalin is
unlikely to occur in significant amounts at this location. Here,
the link between megalin and the (pro)renin receptor may be of
particular interest.
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